Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence

Executive Summary

Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.


Related Content

ViroMed Steps Up Global Ambitions With New Gene Therapy Pipeline
Samsung's Ontruzant Becomes First Trastuzumab Biosimilar Approved In EU
Samsung Looks Beyond Biosimilars Via Takeda Tie-Up
Liver Cancer: What's Close To The Market
Celltrion's Herceptin Biosimilar One Step Closer To US FDA Approval
Celltrion’s Biosimilar Rituximab First In Line For FDA Review
Discounts Will Be Key Factor In US Uptake Of Samsung's Renflexis
Celltrion's Truxima First Biosimilar MAB In Oncology To Win EU Approval
Prosecutors Raid Hanmi HQ As Olmutinib Probe Gets Serious
Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts